Company Analysis

Vyome Holdings, Inc. (HIND)

Nasdaq: HIND · Pharmaceutical Preparations · San Clemente, CA · filing with the SEC since 2008
Grade2.7
◀ Past 1.4● Present 1.8▶ Future 4.2
1 est.
The companyfiscal 2025, as filed
Revenue$319,714+24.4%
Net income-$10.3M-609.0%
Earnings per share$-4.86+99.9%
Operating cash flow-$3.7M-510.4%
Cash$5.0M+4789.2%
Debtn/a
Shareholders’ equity$3.8M+185.7%
Shares, diluted2,161,342+896722.4%
Return on equity-272.8%
The recordfrom its filings
Filings in 202615
Newest filingNov 12 · 10-Q
Annual reportMar 18, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted53
Filer category<br>Emerging growth company
Trailing twelve months to Sep 2026Revenue $153,095Net income -$3.8MCash from operations -$4.5Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Sep 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 28, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 25, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Aug 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
May 29, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
May 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Apr 29, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Mar 31, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton HIND · research, not advice